Zevra Therapeutics, Inc. $ZVRA Stake Boosted by Carret Asset Management LLC

Carret Asset Management LLC increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 9.7% during the second quarter, HoldingsChannel reports. The firm owned 39,640 shares of the company’s stock after acquiring an additional 3,500 shares during the period. Carret Asset Management LLC’s holdings in Zevra Therapeutics were worth $349,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Rhumbline Advisers increased its stake in Zevra Therapeutics by 9.6% in the 1st quarter. Rhumbline Advisers now owns 74,585 shares of the company’s stock worth $559,000 after purchasing an additional 6,532 shares in the last quarter. Strs Ohio purchased a new position in Zevra Therapeutics in the 1st quarter worth about $125,000. Woodline Partners LP increased its stake in Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after purchasing an additional 476,032 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after purchasing an additional 1,812 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. increased its stake in Zevra Therapeutics by 6.9% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company’s stock worth $4,121,000 after purchasing an additional 35,348 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Insider Activity

In other news, CEO Neil F. Mcfarlane sold 19,500 shares of Zevra Therapeutics stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $10.82, for a total transaction of $210,990.00. Following the completion of the sale, the chief executive officer directly owned 222,016 shares in the company, valued at $2,402,213.12. The trade was a 8.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John B. Bode purchased 5,000 shares of Zevra Therapeutics stock in a transaction dated Tuesday, August 19th. The shares were purchased at an average price of $9.16 per share, with a total value of $45,800.00. Following the completion of the acquisition, the director owned 45,000 shares in the company, valued at $412,200. The trade was a 12.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Trading Up 0.2%

Shares of NASDAQ ZVRA opened at $10.14 on Friday. Zevra Therapeutics, Inc. has a one year low of $6.19 and a one year high of $13.16. The firm has a market capitalization of $569.16 million, a PE ratio of -48.29 and a beta of 1.49. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $9.51 and a two-hundred day moving average price of $9.44.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($1.49). The firm had revenue of $25.88 million for the quarter, compared to analyst estimates of $22.49 million. Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. As a group, analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Zacks Research cut Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. JMP Securities decreased their price objective on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 13th. Wall Street Zen lowered Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 20th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Tuesday, October 14th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.